1396238--3/31/2009--IRIS_BIOTECHNOLOGIES

related topics

{product, candidate, development}

{product, liability, claim}

{stock, price, share}

{personnel, key, retain}

{product, market, service}

{control, financial, internal}

{stock, price, operating}

{regulation, change, law}

{provision, law, control}

{property, intellectual, protect}

Risks Related to Our Financial Results We Are A Development Stage Company And May Never Commercialize Any Of Our Products Or Earn A Profit. We Will Need To Raise Additional Capital To Commercialize Our Nano-BioChip Technology, and Our Failure To Obtain Funding When Needed May Force Us To Delay, Reduce or Eliminate Our Product Development Programs. If We Fail To Maintain Effective Internal Controls Over Financial Reporting, The Price Of Our Common Stock May Be Adversely Effected. Risks Related To Our Business The Commercial Success Of Our Products Will Depend On The Degree Of Market Acceptance Of These Products Among Physicians, Patients, Health Care Payors And The Medical Community. Our Financial Results Will Initially Depend On Sales Of One Product, The Nano-BioChip Gene Expression Kit And We Will Need To Generate Sufficient Revenues From This Product To Run Our Business. At Present, Our Success Depends Solely On the Successful Commercialization of Our Nano-Biochip Technology for Our Proposed Use As A Cancer Diagnostic Analysis Tool. If We Fail to Comply With FDA Requirements, Or Fail to Obtain Regulatory Approval, We May be Limited or Prohibited In Our Ability to Commercialize Our Products and May Be Subject to Stringent Penalties. If We Are Unable To Develop Products To Keep Pace With Rapid Medical And Scientific Change, Our Operating Results And Competitive Position Would Be Harmed. Our Competitive Position Depends On Maintaining Intellectual Property Protection. If We Are Unable To Compete Successfully, We May Be Unable To Generate Revenues Or Achieve Profitability. Our Research And Development Efforts Will Be Hindered If We Are Not Able To Contract With Third Parties For Access To Archival Tissue Samples. Changes In Healthcare Policy Could Subject Us To Additional Regulatory Requirements That May Interrupt Commercialization Of The Nano-BioChip Gene Expression Kit And Increase Our Costs. If We Cannot Enter Into Clinical Collaborations, Our Product Development Could Be Delayed. We Are Dependent Upon Key Personnel And Consultants And The Loss Of Any Key Member Of This Team Could Have A Material Adverse Effect On Our Business. We Are Controlled By Current Officers, Directors And Principal Stockholders. Provisions In Our Charter Documents Could Discourage A Takeover That Stockholders May Consider Favorable. Risks Related To Our Common Stock There is not now, and there may not ever be an active market for shares of our common stock. Our Common Stock Is Subject To The Penny Stock Rules Of The SEC.

Full 10-K form ▸

1396238--3/31/2009--IRIS_BIOTECHNOLOGIES_INC